Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liothyronine + sertraline
- Development stage
- Phase 4
- Lead developer
- Ipe
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Liothyronine + sertraline is a combination of two pharmaceutical drugs used in clinical research for the treatment of major depressive disorder. Liothyronine (triiodothyronine, T3) is a synthetic form of the thyroid hormone that regulates metabolism and has been investigated as an adjunct to antidepressant therapy. Sertraline is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for depression. The rationale for combining these agents stems from evidence that thyroid hormones may potentiate or accelerate antidepressant effects. Clinical trials have shown mixed results regarding efficacy; some studies report enhanced response and remission rates when liothyronine is added to sertraline in patients with major depressive disorder, while others do not find significant benefit over monotherapy[1][2][5]. The combination appears generally well tolerated without significant increases in adverse effects compared to monotherapy[1][2][7].
- Other names
- liothyronine and sertralinetriiodothyronine and sertralineT3 and sertralineT-3 and sertralineT 3 and sertraline
02
Targets
SERT (Sodium-dependent serotonin transporter)THRA (Thyroid hormone receptor alpha)THRB (Thyroid hormone receptor beta)
Beyond the preview
Go deeper on liothyronine + sertraline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liothyronine + sertraline.